+234.4%
AMD vs MRNA
+444.4%
-210.0%
-27.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.0% | -3.4% | +6.4% | +3.1% |
| 7D | +14.0% | -10.1% | +24.1% | +14.1% |
| 30D | +11.0% | +126.7% | -115.8% | +7.9% |
| 3M | +9.6% | +184.1% | -174.5% | -1.5% |
| 6M | +157.1% | +143.3% | +13.8% | +138.1% |
| YTD | +143.3% | +359.9% | -216.5% | +106.4% |
| 1Y | +234.4% | +454.2% | -219.8% | +200.4% |
| All | +234.4% | +444.4% | -210.0% | +200.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling